References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30. doi: 10.3322/caac.21590
- Bryan DS, Donington JS. The role of surgery in management of locally advanced non-small cell lung cancer. Curr Treat Option Oncol 2019; 20: 27. doi: 10.1007/s11864-019-0624-7
- Jeremic B. Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapy. Clin Lung Cancer 2015; 16: 80-5. doi: 10.1016/j.cllc.2014.08.003
- Burdett S, Parmar MKB, Steward LA, Souhami RL, Arriagada R, Girling DJ, et al; PORT Meta-analysis Trialists Group. Post-operative radiotherapy in non-small cell lung cancer: a systematic meta-analysis using individual data from nine randomised controlled trials. Lancet 1998; 352: 257-63.
- Sakib N, Li N, Zhu X, Li D, Li Y, Wang H. Effect of postoperative radiotherapy on outcome in resectable stage IIIA-N2 non-small-cell lung cancer: an updated meta-analysis. Nucl Med Commun 2018; 39: 51-59. doi: 10.1097/MNM.0000000000000764
- Le Pechoux C, Pourel N, Barlesi F, Faivre-Finn C, Lerouge D, Zalcman G, et al. LBA3_PR - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK) NCT00410683. [Abstract]. Ann Oncol 2020; 31(Suppl 4): S1178-S1178.
- Matsuguma H, Nakahara R, Ishikawa Y, Suzuki H, Inoue K, Katano S, et al. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved Interact Cardiovasc Thorac Surg 2008; 7: 573-7. doi: 10.1510/icvts.2007.174342
- Wang S, Ma Z, Yang X, Wang Y, Xu Y, Xia W, et al. Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number. Radiat Oncol 2017; 12: 207. doi: 10.1186/s13014-017-0946-1
- Shang X, Li Z, Lin J, Wang H, Wang Z. PLNR</=20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study. Cancer Manag Res 2018; 10: 3561-7. doi: 10.2147/CMAR.S173856
- Nguyen SK, Masson-Cote L, Fortin A, Dagnault A. Influence of smoking status on treatment outcomes after post-operative radiation therapy for non-small-cell lung cancer. Radiother Oncol 2010; 96: 89-93. doi: 10.1016/j. radonc.2010.05.008
- Yoshino I, Yoshida S, Miyaoka E, Asamura H, Nomori H, Fujii Y, et al. Surgical outcome of stage IIIA-cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004. J Thorac Oncol 2012; 7: 850-5. doi: 10.1097/JTO.0b013e31824c945b
- Kou P, Wang H, Lin J, Zhang Y, Yu J. Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis. Future Oncol 2018; 14: 2371-81. doi: 10.2217/fon-2018-0326
- Kumar V, Robbins SL, Abbas AK, Aster JC. Robbins basic pathology. 9th edition. Philadelphia, PA: Elsevier/Saunders; 2013.
- Pasche B, Grant SC. Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. JAMA 2014; 311: 1975-6. doi: 10.1001/jama.2014.3742
- Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012; 18: 2443-51. doi: 10.1158/1078-0432.CCR-11-2370.
- Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, Decamp MM. Factors associated with local and distant recurrence and survival in patients with resected non-small cell lung cancer. Cancer 2009; 115: 1059-69. doi: 10.1002/cncr.24133
- Dai H, Hui Z, Ji W, Liang J, Lu J, Ou G, et al. Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. Oncologist 2011; 16: 641-50. doi: 10.1634/theoncologist.2010-0343
- Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017; 151: 193-203. doi: 10.1016/j. chest.2016.10.010
- Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgenszternet D, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol 2015; 33: 870-6. doi: 10.1200/JCO.2014.58.5380
- Zou B, Xu Y, Li T, Li W, Tang B, Zhou L, et al. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys 2010; 77: 321-8. doi: 10.1016/j.ijrobp.2009.05.044
- Liu T, Mu Y, Dang J, Li G. The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis. J Cancer 2019; 10: 3941-9. doi: 10.7150/jca.28680
- Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14: 535-46. doi: 10.1038/nrc3775
- Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the management of lung cancer. J Thorac Dis 2013; 5(Suppl 5): S463-78. doi: 10.3978/j.issn.2072-1439.2013.08.43
- Moretti L, Yu DS, Chen H, David P, Carbone DP, Johnson DH, Keedy VL, et al. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Oncologist 2009; 14: 1106-15. doi: 10.1634/theoncologist.2009-0130
- Koutsoukos K, Mountzios G. Novel therapies for advanced squamous cell carcinoma of the lung. Future Oncol 2016; 12: 659-67. doi: 10.2217/fon.15.358
- Feng QF, Wang M, Wang LJ, Yang ZY, Zhang YG, Zhang DW, et al. A study of postoperative radiotherapy in patients with non–small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 2000; 47: 925-9. doi: 10.1016/S0360-3016(00)00509-5
- Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315: 1377-81. doi: 10.1056/NEJM198611273152202
- Hui Z, Dai H, Liang J, Lv J, Zhou Z, Feng Q, et al. Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy. Thorac Cancer 2015; 6: 346-53. doi: 10.1111/1759-7714.12186
- Consonni D, Pierobon M, Gail MH, Rubagotti M, Rotunno M, Goldsteinet A, et al. Lung cancer prognosis before and after recurrence in a population-based setting. J Natl Cancer Inst 2015; 107: v59. doi: 10.1093/jnci/djv059
- Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27. doi: 10.1016/S1470-2045(06)70804-X
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39. doi: 10.1056/NEJMoa040938
- Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34. doi: 10.1200/JCO.2012.44.2806
- Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42. doi: 10.1016/S1470-2045(11)70184-X
- Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8. doi: 10.1056/NEJMoa0909530
- Zhong W, Wang Q, Mao W, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19: 139-48. doi: 10.1016/S1470-2045(17)30729-5
- Tang W, Li X, Xie X, Sun X, Liu J, Zhang J, et al. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. Lung Cancer 2019; 136: 6-14. doi: 10.1016/j.lungcan.2019.08.001
- Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001; 31: 139-48. doi: 10.1016/s0169-5002(00)00181-1
- Yeh SJ, Chang CA, Li CW, Wang LH, Chen BS. Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification. Oncotarget 2019; 10: 3760-806. doi: 10.18632/oncotarget.26940
- Li N, Zhao J, Ma Y, Roy B, Liu R, Kristiansen K, et al. Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma. Oncol Lett 2018; 16: 3992-4000. doi: 10.3892/ol.2018.9113
- Lin YK, Hsu HL, Lin WC, Chang JH, Chang YC, Chang CL, et al. Efficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancer. Oncotarget 2017; 8: 35280-8. doi: 10.18632/onco-target.13257